NCT05285540View on ClinicalTrials.gov

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
Friedreich Ataxia
Interventions
DRUG

DT-216

DT-216 will be administered by intravenous (IV) injection

DRUG

DT-216 matching Placebo

Placebo will be administered by intravenous (IV) injection

Trial Locations (1)

07724

Clinilabs, Eatontown

Sponsors
All Listed Sponsors
lead

Design Therapeutics, Inc.

INDUSTRY

NCT05285540 - Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia | Biotech Hunter | Biotech Hunter